RemeGen Co., Ltd.*
榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

INSIDE INFORMATION
Announcement on Signing a License Agreement with AbbVie

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司(the "**Company**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") as well as the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Overview of the Agreement

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on January 12, 2026 (after trading hours), the Company entered into an exclusive licensing agreement (hereinafter referred to as the "**Agreement**") with an AbbVie controlled company (hereinafter referred to as "**AbbVie**") regarding RC148. RC148 is a novel PD-1/VEGF targeting bispecific antibody drug developed by the Company. According to the Agreement, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize RC148 outside the Greater China region (hereinafter referred to as the "**The Scope of Collaboration**"). Upon the Agreement's effectiveness, which is subject to regulatory clearance, the Company will receive an upfront payment of USD $650 million and is eligible to receive up to USD $4.95 billion in development, regulatory, and commercial milestone payments, as well as tiered double-digit royalty payments on net sales outside the Greater China region. The milestone payments stipulated in the Agreement are subject to certain conditions, and the final milestone payment amounts achieved by the Company remain uncertain.

This transaction has been reviewed and approved by the Board of Directors and does not require approval by the shareholders' meeting.

About AbbVie in Oncology

AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. AbbVie is advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. AbbVie focuses on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. It achieves this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. AbbVie's dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. For more information, please visit http://www.abbvie.com/oncology.

To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, AbbVie and its ultimate beneficial owners are third parties independent of the Company and its connected persons.

About RC148

RC148 is a novel PD-1/VEGF targeting bispecific antibody drug being developed by the Company. It is designed to activate anti-tumor immune responses while disrupting tumor-driven angiogenesis. By simultaneously targeting and blocking the PD-1 and VEGF pathways, it is expected to enhance the anti-tumor activity of the immune system through multiple mechanisms. RC148 is currently being developed in China by the Company as a monotherapy and in combination for treating patients with various advanced malignant solid tumors.

Key Terms of the Agreement

(I) The Scope of Collaboration

The Company is licensing RC148, for which it holds proprietary intellectual property rights, to AbbVie. Under the Agreement, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize the licensed products outside the Greater China region.

(II) Financial Terms

Upon the Agreement's effectiveness, the Company will receive an upfront payment of USD $650 million and is eligible to receive up to USD$4.95 billion in development, regulatory, and commercial milestone payments, as well as tiered double-digit royalty payments on net sales outside the Greater China region.

(III) Duration of the Agreement

The Agreement becomes effective following the receipt of applicable regulatory clearances and shall remain in full force and effect unless terminated earlier in accordance with other provisions of the Agreement.

Impact of This Licensing Transaction on the Company

This licensing transaction will accelerate the global development and commercialization process of RC148, provide innovative treatment options for patients worldwide, and enhance the Company's brand value and international influence. The Agreement will not affect the independence of the Company's overall operations and will not incur any potential detrimental impact to the interests of the Company or its shareholders.

Listing Rules Implications

As the transaction contemplated under the License Agreement is of a revenue nature in the ordinary and usual course of business of the Company, pursuant to Rule 14.04(1)(g) of the Listing Rules, the transaction contemplated thereunder does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

Risk Disclosure

As innovative drug development is characterized by high technology, high risk, and high added value, and the cycle from early-stage research, clinical trials, regulatory approval to production is long and involves many steps, the process is susceptible to various uncertainties. The payments stipulated in the Agreement are subject to certain conditions, and the final payment amounts remain uncertain. The Company will actively advance the Agreement in accordance with relevant regulations and strictly fulfill the information disclosure obligations regarding subsequent developments of the Agreement in a timely manner as required. Investors are advised to exercise prudence in their decision-making process and be mindful of investment risks.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive Director

Yantai, The People's Republic of China
January 12, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai and Mr. Lin Jian as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.

* *For identification purpose only*